Hepatic Arterial Therapy with Drug-Eluting Beads in the Management of Metastatic Pancreatic Carcinoma to the Liver: A Multi-Institutional Registry by Kotoyan, Raffi et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2012, Article ID 168303, 6 pages
doi:10.1155/2012/168303
Research Article
Hepatic Arterial Therapy with Drug-Eluting Beads in
the Management of Metastatic Pancreatic Carcinomato
the Liver: A Multi-Institutional Registry
RafﬁKotoyan,1 Tiffany Metzger,1 CliffTatum,2 Ken Robbins,3 andR o be rtC.G.M artinII 1
1Division of Surgical Oncology, Department of Surgery, University of Louisville School of Medicine, 315 East Broadway, Room 311,
Louisville, KY 40292, USA
2Norton Radiology, Norton Hospital, 301 South Floyd Street, Louisville, Ky 40202, USA
3Baptist Health, Little Rock, AR 23011, USA
Correspondence should be addressed to Robert C. G. Martin II, robert.martin@louisville.edu
Received 28 September 2011; Revised 28 November 2011; Accepted 1 December 2011
Academic Editor: Dirk Arnold
Copyright © 2012 Raﬃ Kotoyan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction. There has been limited reporting on the use of hepatic-directed therapy in liver dominant hepatic metastases arising
from pancreatic cancer. Methods. An IRB-approved prospective multi-institutional treatment registry of 885 patients undergoing
1458 treatments for primary or secondary cancers in the liver was evaluated from January 2007 to January 2011. Results. Ten pa-
tients underwent a total of 17 treatment sessions with drug-eluting beads (DEBs). Six patients received concurrent chemotherapy
while undergoing DEB with no severe adverse events. After a median followup of 16 months, the 6- and 12-month response rates
were80%and75%,respectively,withamedianoverallsurvivalof9.3months.Conclusion.HepaticarterialtherapywithDEBcanbe
safely and eﬀectively used in selected patients with liver predominant metastatic disease from pancreatic cancer. This therapy
should be considered in combination with systemic chemotherapy as a possible second therapy given the limited response rates of
second-line chemotherapy.
1.Introduction
Pancreaticcancerisamajorcauseofcancer-relatedmortality
worldwide as it ranks as the 5th leading cause of death, with
an annual incidence in certain countries of approximately
20,000–40,000 cases and poor mortality rates [1]. Owning
to the high frequency of local extension and/or metastatic
disease at the time of diagnosis, only a small minority of
patients are candidates for curative resection. Moreover, sur-
gery alone is limited, with an unsatisfactory prognosis and a
high incidence of postoperative recurrence. To improve the
survival of patients with pancreatic cancer, eﬀective multi-
modality treatments are demonstrating eﬀective disease con-
trol and prolongation of quality of life time. A recent rando-
mized controlled study demonstrated that treatment with
gemcitabine exhibited a better clinical beneﬁt response
(CBR) (23.8 versus 4.8%) and median survival period (5.65
versus 4.41 months) than bolus 5-ﬂuorouracil (5-FU) [2].
However, current chemotherapy regimens for pancreatic
cancer must continue to be improved since gemcitabine
alone oﬀers limited survival beneﬁt. Gemcitabine adminis-
tration with a ﬁxed dose-rate infusion [3] and gemcita-
bine combination regimens have been investigated, but a
meaningful impact on survival, compared with that of gem-
citabine monotherapy, has not been reached. Recent ran-
domized phase III studies of gemcitabine plus erlotinib [4]
and gemcitabine plus capecitabine [5] have demonstrated
signiﬁcant survival beneﬁt, but a consensus on the optimal
ﬁrst line therapy has not been agreed upon.
Liver dominant and liver refractory metastatic diseases
still remain common problems in the management of meta-
static pancreatic cancer. Transcatheter arterial embolization
(TAE)andtranscatheterarterialchemoembolization(TACE)
are increasingly used as regional therapeutic modalities for
the treatment of unresectable hepatic malignancies [6]. In
general, TAE and TACE have been used when surgical2 Journal of Oncology
resection and/or systemic therapy have failed to produce an
adequate response or when conventional therapy has been
known to be ineﬀective [7]. There has been almost no infor-
mation reported on the use of TACE in hepatic metastases
arising from pancreatic cancer.
Drug-eluting bead TACE is a drug delivery system that
combines the local embolization of vasculature with the rel-
ease of chemotherapy into adjacent tissue. Its administration
is similar to that of conventional TACE, and it represents
a minimally invasive procedure performed by intervention-
al radiologists [8, 9]. The beads occlude vasculature, causing
embolization, and the chemotherapy is delivered locally.
Early phase 1 and nonrandomized phase 2 studies have con-
ﬁrmed the ability of this device to deliver a local, controlled,
sustained dose of doxorubicin to the tumors, with minimal
systemic doxorubicin exposure [10]. A recently completed
randomized phase 2 study demonstrated that these drug-
elutingdoxorubicinbeadshadimprovedresponserateswhen
compared to conventional TACE in advanced HCC and sig-
niﬁcantly less overall adverse events, including doxorubicin-
related side eﬀects [11]. Therefore, we conducted a prospec-
tive observational study to evaluate the safety and eﬃcacy of
hepaticarterialtherapyinthemanagementofliverdominant
or liver refractory metastatic pancreatic cancer.
2.MaterialsandMethods
An IRB-approved prospective multi-institutional treatment
registry of 805 patients undergoing 1358 treatments for pri-
mary or secondary cancers in the liver was evaluated from
January 2007 to January 2011. Of the 805 patients, 10 pa-
tients presented with liver dominant metastatic pancreatic
cancer to the liver and were treated with doxorubicin or irin-
otecan drug-eluting beads. The registry was designed to sat-
isfy the strict criteria for critical appraising of the quality of
a registry study with (1) a well-described patient population,
(2) hypothesis generating and answering questions, (3) high
qualitydata,withgoodqualitycontrol,(4)independentasse-
ssment of outcomes, (5) good clinically relevant followup
with minimal loss of patients, and (6) comparable patient
evaluation across all institutional participating [12].
Patients were included for therapy if they were 18 years
of age or older, of any race or sex, had histologic and radi-
ologic proof of metastatic pancreatic cancer to the liver by
percutaneousbiopsy,wereabletogiveinformedconsent,and
were eligible for treatment as previously described [13, 14].
PatientsmusthavehadanECOGperformancestatusscoreof
less than or equal to 2 with a life expectancy of greater than
or equal to 3 months, nonpregnant with an acceptable con-
traceptive in premenopausal women. Exclusion to therapy
was contraindication to angiographic and selective visceral
catheterization, signiﬁcant extrahepatic disease, representing
an eminent life-threatening outcome, greater than 75% of
hepatic parenchymal involvement, severe liver dysfunction,
pregnancy, and severe cardiac comorbidities. Only patients
with liver dominant (deﬁned as greater than 50% of the
overall total disease burden) were considered for treatment.
Patients were followed for any treatment-related adverse
experiences for 30 days after each treatment and monitored
for survival for two years. Follow-up assessments included
a triphase CT scan of the liver within at least one to two
months from the treatment completion with the evaluation
of the enhancement pattern of the target lesion and tumor
response rates measured according to modiﬁed RECIST
criteria [15].
The decision to treat with DEB was based on either the
need to dose reduce chemotherapy based on toxicity and
maintain disease control or because of hepatic speciﬁc pro-
gression. Given that it is well established that pancreatic ade-
nocarcinoma is a systemic disease, the use of concurrent
chemotherapy and DEB was performed in all patients. The
use of DEB in neuroendocrine (NET) tumors was based on
the established disease biology and the extent of liver in-
volvement.
3. Image-GuidedInfusion Technique
Deﬁning the amount of liver disease was integral to deﬁning
both the number of treatments and the type of catheter
position and therapy that would be performed. For ﬁnite
numbers of lesions, deﬁned as less than four lesions, a treat-
ment cycle was planned for a minimum of two dosing sche-
dules of at least 100mg of DEBDOX to 150mg of DEBDOX
[16, 17] loaded in two bead vials or 100mg DEBIRI [18]
loaded in one vial. Bead size of 100 to 300 microns was rec-
ommended. Treatment intervals are planned for every four
to eight weeks. If toxicity and performance status changes
during treatment, the intervals between DEB are extended.
Repeat abdominal imaging every three months from the ini-
tialﬁrsttreatmentcycleisrecommendedtoevaluateresponse
as well as planned retreatment. A treatment cycle is deﬁned
astreatmentofallliverdisease.Atreatmentishepaticarterial
chemotherapy to one single lobe, which could also be a treat-
ment cycle if a patient has only unilobar disease.
For diﬀuse disease, a plan of a minimum of four doses
of 100 to 150mg (depending on the extent of tumor burden
and the extent of hepatic parenchyma reserve) is loaded into
one or two bead vials of the similar size as above with the
plan for at least two treatments per lobe with every three to
four week dosing schedule, following toxicity, and extending
the interval if toxicity was seen with planned repeat CT scan
three months from the ﬁrst dose to evaluate tumor response.
For example, if patients present with bilobar disease, they
would receive the ﬁrst bead treatment to the right lobe, then
three weeks after the second bead treatment to the left lobe,
then three weeks later third bead treatment to the right lobe,
and then again three weeks later to the left lobe. The reason
for lobar infusion is based on the desire for drug delivery
and less on inducing stasis in patients with multifocal
lobar disease that is not amenable to superselective delivery.
Additional embolic material is not recommended since prior
studies have demonstrated the increase in adverse events but
no beneﬁt in response rates.
All bead therapies were performed with the DC/LC bead
microspheres (Drug-Eluting Bead (DEB); http://www.bio-
compatibles.com/, Biocompatibles UK, Surrey, UK).Journal of Oncology 3
Table 1: Clinical demographics for liver dominant metastatic pan-
creatic cancer DEBIRI-treated patients.
Characteristics N = 10
Pancreatic primary
Pancreatic adenocarcinoma
Neuroendocrine
6
4
Age (years) (median, range) (69, 45–77)
Body mass index (median, range) 23.8
(16.6–32.3)
Gender
Male
Female
4
6
Past medical history
Cardiac
Vascular
Pulmonary
Diabetes
Insulin
Non-insulin
Alcohol
Tobacco
Median pack year smoking
Hypertension
Prior cholecystectomy
0
0
1
3
2
1
1
2
40
5
2
Karnofsky Performance Scale, median %
(range) 100 (80–100)
Extent of liver lesions
Distinct number
Numerous
6
4
Liver involvement
<25%
26–50%
7
3
Number liver tumors (median, range)
1
2
≥3
(2, 1–3)
1
4
5
Sum of target lesion(s) size (median, range) 3.9cm (1–10)
Extrahepatic disease
Para-aortic lymph node
Lung, adrenal
Pancreatic primary
3
1
1
1
Lesion location
Seg 2–4
Seg 4–8
Seg 5–8
Other
0
1
3
6
4. Results
Ten patients underwent a total of 17 treatment sessions with
drug-eluting beads (DEBs) (Table 1). There were 6 females
and 4 males with a median age of 69 years and a range of
45 to 77 years. All patients’ cardiac and vascular medical his-
tories were negative. 2 had a history of tobacco use with a
median 40 pack per year history. Three had diabetes, 2 of
which were insulin dependent. Only 2 of the patients had
had prior cholecystectomies. The patients had a median
Karnofsky Performance Scale of a 100%.
All 10 patients had a primary pancreatic tumor; 6 (60%)
with an adenocarcinoma or 4 (40%) with a neuroendocrine
tumor (NET). Six patients had a distinct number of hepatic
lesions, and 4 patients had lesions which could not be quan-
tiﬁed. Seven (70%) patients had <25% liver involvement,
while 3 (30%) had 26–50% liver involvement.
Of the 10 patients, 2 (20%) had undergone a prior liver
resection (Table 2). Seven (70%) patients (6 with adeno and
1 with NET) had had prior chemotherapy; 4 with Gemc-
itabine and 1 each with FOLFOX, FOLFIRI, and Doxoru-
bicin/Streptozocin. In these 6 patients with adenocarcinoma,
5hadgrade3-4eitherhematologicorneurologictoxicitythat
led to either a dose-delayed, dose-limiting toxicity or discon-
tinuation of one of the chemotherapeutic agents. Four pa-
tients had local liver lesion disease progression with either
new lesions or the growth of established lesions while on
chemotherapy. Three patients had had prior trans-arterial
chemoembolization (TACE); 2 with CAM and 1 with carbo-
platin, with only stable disease as best response and the rea-
sonforDEBtherapy.Finally,6(60%)patientswereundergo-
ingconcurrentchemotherapy,eithertocontrolsmallvolume
extrahepatic disease or based on the desire of the treating
multidisciplinary team in order to obtain synergistic results
with systemic chemotherapy and DEB therapy.
Therewere17totaltreatments,withamedianof1.5bead
courses per patient, ranging from 1 to 3 courses per patient
(Table 3). All 17 (100%) of the treatments were considered a
technical success. Pancreatic adenocarcinoma patients were
alltreatedwithIrinotecanbeads,andNETpatientweretreat-
ed with doxorubicin beads. The total hepatic dose exposure
for all the irinotecan beads was 250, with a range of 100 to
400, and 150 for the Doxorubicin beads with a range of 100
to450.For13(76%)ofthetreatments,weutilized100to300
micronbeads,and,fortheremaining4(24%)treatments,we
chose to use 300 to 500 micron beads. There were minimal
hematologicchangesduetothetreatments.Labvaluesshow-
ed an average decrease of 0.23 cells/µL in white blood cells
(range of −0.45–3.00cells/ul). On average, a patient’s hemo-
globinincreasedby0.8g/dL(range−1.1–2.1g/dL).Inacom-
plete evaluation of all hematologic parameters, there were
no grade 2 or greater hematologic toxicities. We found only
minimal changes in overall hematologic values as long as
established bead size, technique, and dosages were utilized.
A total of 7 adverse events consisting of vomiting, pain,
nausea, and gastritis were recorded (Table 4). None of these
adverse events were grade 3 or higher, which was the cutoﬀ
for being considered a severe adverse event. The vomiting,
pain,andnauseawereconsistentwithpostembolicsyndrome
a n dw e r ef o u n dt ob er e l a t e dm o r ec o m m o n l yt oD E B I R I
administration in the adenocarcinoma patients. The one
NET patient reported grade 1 gastritis that was controlled
with oral medication.
The patients were set to be followed at 3, 6, 9, 12, and
18months.Theirresponseratesweremeasuredusingamod-
iﬁed Response Evaluation Criteria in Solid Tumors (mRE-
CIST) Criteria (Table 5). No patients died due to complica-
tions of the procedure within 90 days of the treatment. At4 Journal of Oncology
Table 2: Prior treatments.
N = 10 Patients
Prior surgical therapy
Liver resection 2
Prior chemotherapy
FOLFOX
FOLFIRI
Gemzar
Doxorubicin and Streptozocin
1
1
4
1
Prior interventional treatment
RFA
TACE—with CAM
TACE—with carboplatin
TAE—with particles
1
2
1
2
Concurrently chemotherapy
FOLFOX
Gemzar
FOLFIRI
Tarceva
2
2
1
1
Table 3: Bead catheter infusion outcomes.
N = total treatments = 17
Number of bead courses Median −1.5
(range) (1–3)
Technical success 100%
Dosage delivered (median, range) (100, 25–150)
Total hepatic dose exposure for all LC
Irinotecan
Doxorubicin
Beads
250mg (100–400)
150mg (100–450)
Bead size utilized
100–300µ
300–500µ
500–700µ
13
4
0
Complications 4 (24%)
Extrahepatic infusion 0
Hematologic changes
WBC
HGB
Bilirubin
−0.23 (−.45–3.0)
0.8 (−1.1–2.1)
0.3 (−0.4–0.8)
Table 4: Bead-infusion-related morbidity.
Adverse events (n = 7) All grades Severe grade∗
Vomiting 2 1
Pain 1 1
Nausea 1 1
Gastritis 1 0
Other 2 0
∗Deﬁned as Grade 3 or higher.
3 months (N = 10), 4 (40%) patients had a complete res-
ponse to their treatment and 6 (60%) patients had a partial
response. At 6 months, 2 patients had died due to their dis-
ease. Of the remaining 8 patients, 3 had a complete response.
At the 9 month interval (N = 8), 2 (25%) patients had
a complete response, 5 (63%) had a partial response, and 1
(13%) had stable disease. At the 12-month followup, 1 more
patient had died of their disease. At this point (N = 7), 2
(25%) patients had stable disease, 2 (25%) had a complete
response, and 3 (50%) had a partial response. Finally, at the
18 month followup (N = 6), 1 other patient had died of
disease. Another patient’s (N = 1) disease had progressed,
1 had a complete response, and 1 had stable disease. At the
time of this writing, 4 patients had still not reached the time
ofthefollowup.Afteramedianfollowupof16months,the6-
and12-monthresponserateswas80%and75%,respectively,
with a median overall survival of 9.3 months.
5. Discussion
There remains limited information and limited clinical
guidelines on the management of the subset of patients with
liver predominant metastasis of pancreatic adenocarcinoma.
However, by using what we know about treating similarly
metastasized neuroendocrine tumors and other treatment
modalities for adenocarcinoma, we hope to gain some better
understanding of how to eﬀectively treat patients with liver
predominant metastatic pancreatic adenocarcinoma.
De Baere et al. demonstrated the safety and eﬃcacy of
DEBDOX with TACE to treat hepatic metastases from well-
diﬀerentiated neuroendocrine tumors [19]. In this study, 20
patients underwent 34 sessions of TACE with DEBs loaded
with Doxorubicin (500–700 micron beads). At 3 months, 80
percent of patients had a partial response, 3 patients had
stable disease, and 1 had progressive disease. Patients had
a median time of 15 months to progression of disease. In
our study, no patients had signs of progression up to 12
months of follow-up. 67% of patients had postembolization
syndrome which lasted less than 7 days, and 5 patients show-
ed signs of TACE-induced peripheral liver necrosis at 1
month. It was concluded that TACE with DEBs was well tole-
rated and safe but needs more studies to deﬁne the best pro-
tocol to use such treatments.
Our study used a maximum of 300–500 micron size
beads as compared to the 500–700 micron beads used in
the study by De Baere et al. While all the patients in their
study had metastatic neuroendocrine tumors, 4 out of 10
(40%) of our patients had neuroendocrine tumors, while the
remaining6(60%)hadprimarypancreaticadenocarcinoma.
While the use of DEBDOX and DEBIRI in liver predom-
inant metastases from pancreatic carcinoma is one modality
to treat this condition, others have proven successful with
ad i ﬀerent approach using TACE. In a recent case report,
Brown et al. examines the complete radiographic response
in a patient with liver isolated metastases from pancreatic
adenocarcinoma [20]. For this particular patient, conven-
tional TACE with gemcitabine and cisplatin was used. This
patient had a grade III poorly diﬀerentiated ductal adeno-
carcinoma that demonstrated hepatic metastasis on a follow-
up CT at 14 months after recovery. The patient underwent
chemoembolization with Gemcitabine and Cisplatin a total
of three times. RECIST criteria were also used to evaluate
this patient’s response. At a 7-month followup, the patientJournal of Oncology 5
Table 5: Response rates for all 10 patients evaluated∗.
Response 3mon
N = 10
6mon
N = 8
9mon
N = 8
12mon
N = 8
18mon
N = 7
C o m p l e t e r e s p o n s e43221
P a r t i a l r e s p o n s e 65540
S t a b l e d i s e a s e 00121
P r o g r e s s i o n o f d i s e a s e 00001
N o t r e a c h e d t i m e p o i n t 00004
D O D 02010
D O C 00000
DOD: dead of disease; DOC: dead of complication.
∗Response rates measured using modiﬁed RECIST Criteria.
showed no evidence of malignancy, and CT/PET showed no
hypermetabolic foci.
Gemcitabine has been used systemically in the past for
the treatment of pancreatic adenocarcinoma with only mar-
ginal activity [21]. The use of gemcitabine using TACE prov-
ed more eﬃcacious in the case report by Brown et al. This
increased response to liver-directed therapy may suggest a
role for TACE in the treatment of liver dominant metastases
from pancreatic adenocarcinoma.
Besides TACE, other treatments of metastatic pancre-
atic adenocarcinoma have been implemented and tested.
Okusaka et al. have reported success using S-1, an oral ﬂuo-
ropyrimidine derivative in patients with metastatic pancre-
atic adenocarcinoma [22]. The patients treated in this study
had inoperable pancreatic cancer and were administered a
predetermined dose of S-1 based on their body surface area.
In total, 144 treatments were administered to 40 patients.
According to RECIST criteria, 0% of patients achieved com-
plete response, 37.5% of patients achieved a partial response,
while 32.5% of patients had progressive disease. The median
time to progression was 3.7 months, and the median survival
time was 9.2 months. This study had a larger patient popu-
lation than our study, but we achieved a comparable median
survival time of 9.3 months.
A limitation of this study may be that diﬀerent doses and
bead sizes were administered to each patient based on the
physician’s discretion. Also, our observations were based on
a small patient population.
While there is much data on the treatment of metastatic
neuroendocrine tumors, we hope to shed some light on
the eﬃcacy of our liver-directed therapy for metastatic pan-
creatic adenocarcinoma. Our study was based on a multi-
institutional registry showing that the data is generalizable
to any institution. While our patients showed some adverse
eﬀects, they were limited to vomiting, pain, and nausea and
none were classiﬁed as severe. The limited toxicity proﬁle of
this treatment is beneﬁcial for the patient with an already
terminal illness. While the median survival of patients with
metastatic pancreatic adenocarcinoma is 3–6 months [23],
we achieved a median overall survival of 9.3 months. Future
studies with reproducible results are needed to establish
this treatment modality as the preferred form for metastatic
pancreatic adenocarcinoma. We believe the results of our
study show promise for its use in the future.
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